Brief: Nanobiotix: First Patient Randomized In US In Phase 3 Pivotal Trial Of NBTXR3 In Head And Neck Cancer

Nanobiotix SA

27/12/2022 07:09

Dec 27 (Reuters) - Nanobiotix SA  NANOB.PA :
    * ANNOUNCES FIRST PATIENT RANDOMIZED IN THE UNITED STATES IN
GLOBAL PHASE 3 PIVOTAL TRIAL EVALUATING RADIOENHANCER NBTXR3 IN
HEAD AND NECK CANCER
    * PHASE 3 FUTILITY ANALYSIS EXPECTED IN 2H 2023, WITH
INTERIM
PHASE 3 DATA EXPECTED IN 2H 2024
    * FIRST PATIENT IN NANORAY-312 WAS RANDOMIZED IN EUROPE BY
NANOBIOTIX IN JANUARY OF 2022, FOLLOWED BY RANDOMIZATION OF
FIRST PATIENT IN ASIA BY NANOBIOTIX' STRATEGIC COLLABORATOR
LIANBIO IN AUGUST OF 2022
    * REMAINS FOCUSED ON EXPANDING TRIAL'S SITE FOOTPRINT,
BUILDING ON
80 SITES CURRENTLY ACTIVATED; DRIVING PATIENT RECRUITMENT; AND
PREPARING FOR PLANNED MILESTONE REPORTING IN 2023

Source text for Eikon:  ID:nGNEntK4D 
Further company coverage:  NANOB.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))